There is a critical need for psychosocial services in the lung cancer care pathway, according to a presentation by Anne-Marie Baird, BS, PhD, on behalf of Lung Cancer Europe (LUCE), […] Read more
Every meeting begins with sharing your story. In summary, this is mine: My name is Liz, and I’m one of your constituents. I was diagnosed with lung cancer 15 years […] Read more
Approximately one-third of patients with NSCLC are diagnosed with unresectable, locally advanced (LA) stage III disease.1 Historically, the standard of care for these patients has been concurrent platinum-based chemotherapy with […] Read more
In August 2010, Dr. Jennifer Temel and her colleagues1 reported in the New England Journal of Medicine that patients who received early palliative care integrated with standard oncologic care from […] Read more
October 26, 2021—The U.S. Federal Trade Commission’s (FTC’s) recently released Cigarette Report1 showed that the number of cigarettes sold increased from 202.9 billion in 2019 to 203.7 billion in 2020. […] Read more
In the past decade, targeting of the PD-1/PD-L1 checkpoint, with or without CTLA-4 targeting, has revolutionized cancer treatment. However, a significant proportion of patients with lung cancer still do not […] Read more
Two studies presented at the WCLC Congress 2021 include data that suggest the potential need to update the current TNM classification of lung cancers by implementing additional pathological elements to […] Read more
Value-based care is getting more attention in lung cancer thanks to two new programs offering significant rebates or full refunds should the therapeutic agent be ineffective or intolerable. Pfizer’s pilot […] Read more